Clinical Trials Arena on MSN
Upstream Bio’s stock drops 47% on verekitug Phase II asthma data
Investors pull away from Upstream as a twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing asthma exacerbations.
Investing.com -- Upstream Bio (NASDAQ:UPB) stock fell 23% after the company reported mixed results from its Phase 2 VALIANT trial of verekitug for severe asthma treatment.
(Alliance News) - NatWest beats annual earnings expectations and boosts shareholder returns, while AstraZeneca reports positive late-stage trial data for Breztri in asthma, as UK retail footfall ...
Throughout a person's lifetime, the cells lining the respiratory tract are exposed to inhaled pollutants, including cigarette ...
Deupirfenidone, a potential new treatment for idiopathic pulmonary fibrosis, is set to be tested in a phase 3 trial this year after a successful phase 2b trial and meeting with the FDA, according to a ...
A new study links telomere length genetics to IPF risk, showing how rare variants and polygenic scores may guide future screening and precision care.
Introduction Dyspnoea is an existentially burdensome symptom in patients with advanced and progressive diseases such as cancer, chronic obstructive pulmonary disease (COPD) and advanced heart failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results